drugset / Trial / NCT00969332

A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease

NCT00969332 ↗

Phase 2 Terminated 62 enrolled University of California, Los Angeles
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate if intravenous fish oil, commercially available as Omegaven, safely and effectively reverses parenteral nutrition associated cholestasis in children.

Timeline

Start
2009-08
Primary completion
2019-01-12
Completion
2019-02-12

Outcome

Met primary endpoint

Stopped: “study intervention was approved by the FDA”

paper 75% in the FO group would experience resolution of cholestasis by 17 weeks vs 6% in the SO group (P < .0001). PMID 23894176 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Omegaven Other / unclassified 1 g/kg Intravenous

Indications